Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications cost effectiveness nusinersen treatment patients infantile onset later onset spinal
… the inclusion of clinical data affect planned or pending publications? Manufacturers should determine the appropriate … attributes. Takeaway 6: Consider developing a section on treatment landscape and unmet need Although not specified in … guidance for development of a UPD or UUD, describing the treatment landscape for the indication can help the payer …
… determine which products provide the greatest benefit to patients while being cost-effective for health plans. With the recently introduced …
… network of evidence to estimate the relative difference in treatment effect of drugs or medical devices. NMA methodology … answer problems such as sparse data, time-to-event data, treatment interaction effects, and how real-world evidence …
… accuracy checks Support for individual country HTAs cost-effectiveness models budget impact analyses clinical and …
Navigating EU Joint Clinical Assessments and Joint Scientific Consultations From January 2025 Onward
… that access to innovative medicines is accelerated for EU patients. Whether the new legislation and centralised process … cut-off for the JCA dossier, epidemiology, and indirect treatment comparisons, these services include systematic … Clinical Assessments: Racing to the Finish Line at What Cost? Advancements in EU Health Technology Regulation and …
… valid methods are used to evaluate COVID-19 vaccine effectiveness in the real world. Bradley Layton, PhD, Senior … methods, and support for performing studies. The Biologics Effectiveness and Safety (BEST) System supports the Sentinel Initiative in monitoring the safety and effectiveness of biologic products. RTI-HS is in the trenches …
… to the conduct of valid and reliable studies on the effectiveness and safety of treatments and vaccines and, …
… of asset and how it compares to comparators); and clinical effectiveness. Non-clinical HTA domains, which mainly involve cost, economic evaluation, and ethical aspects remain with … that access to innovative medicines is accelerated for EU patients in the EU. Whether the new legislation and …
… characterizations or conclusions regarding the safety or effectiveness of the unapproved product or the unapproved … from Phase 1, Phase 2, and Phase 3 studies (peer-reviewed publications; congress abstracts, posters, and presentations; … likely not possible Economic Value and Modeling Report - cost-effectiveness model and BIM Economic Information - …
… cell disease, multiple sclerosis, migraine disorders, spinal muscular atrophy, Alzheimer's disease, Parkinson's …